Sanaria’s innovative vaccines based on live attenuated sporozoites have shown excellent efficacy in trials in the United States, Germany, and multiple countries in Africa.

Post-licensure, Sanaria’s efforts will focus on delivering PfSPZ Vaccine to individuals and communities for personal protection and focal elimination respectively, as well as improving the potency and decreasing the cost of goods by developing second and third generation PfSPZ-based malaria vaccines.

Our long-term goal is to use PfSPZ-based malaria vaccines to immunize entire populations in geographically defined areas in order to halt malaria transmission and eliminate malaria.

In a related endeavor Sanaria has collaborated with NIH to develop a human monoclonal antibody (HmAb – CIS43) directed toward the circumsporozoite protein of Plasmodium falciparum (US Pat No. 11,021,535) and proven in clinical trials to be effective in providing 100% protection against controlled human malaria infection at 8 weeks after the last dose of vaccine (Lyke KE et al., Lancet Infect Dis.  Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial.  2023 23:578), and 70% to 90% protection of Malian adults against field transmission of Pf for 6 months (Kayentao K, et al. N Engl J Med. Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali. 2022 387:1833).

Since this HmAb approach can be substituted for a PfSPZ vaccine and because protection results rapidly from a single dose, Sanaria is presently collaborating with others to commercialize highly effective HmAbs as a stand-alone tool for those individuals for whom PfSPZ vaccines may not be appropriate or adequate, as well as for travelers or military scheduling an immediate trip to a high-risk area. HmAb will also be useful in elimination campaigns as an alternative approach for those individuals for whom PfSPZ vaccines prove to be inappropriate or inadequate.

Learn more about Sanaria’s vaccine pipeline, our facilities and our products and services.